{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:51:34Z","timestamp":1761519094744,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.4158\/ep13127.ra","type":"journal-article","created":{"date-parts":[[2013,10,14]],"date-time":"2013-10-14T21:08:02Z","timestamp":1381784882000},"page":"84-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pasireotide and Mifepristone: New Options in the Medical Management of Cushing's Disease"],"prefix":"10.1016","volume":"20","author":[{"given":"Pejman","family":"Cohan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP13127.RA_bb0005","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2265.1994.tb02486.x","article-title":"Morbidity and mortality in Cushing\u2019s disease: an epidemiological approach","volume":"40","author":"Etxabe","year":"1994","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.4158\/EP13127.RA_bb0010","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","article-title":"Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement","volume":"93","author":"Biller","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP13127.RA_bb0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jocn.2010.05.001","article-title":"Management of recurrent Cushing\u2019s disease","volume":"18","author":"Liubinas","year":"2011","journal-title":"J Clin Neurosci."},{"key":"10.4158\/EP13127.RA_bb0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4137\/CMO.S6198","article-title":"Treatment options in Cushing\u2019s disease","volume":"6","author":"Rizk","year":"2012","journal-title":"Clin Med Insights Oncol."},{"key":"10.4158\/EP13127.RA_bb0025","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2265.2000.00958.x","article-title":"Treatment of pituitary-dependent Cushing\u2019s syndrome: long-term results of unilateral adrenalectomy followed by external pituitary irradiation compared to transsphenoidal pituitary surgery","volume":"52","author":"Nagesser","year":"2000","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.4158\/EP13127.RA_bb0030","doi-asserted-by":"crossref","DOI":"10.3171\/foc.2007.23.3.7","article-title":"Transsphenoidal surgery for Cushing\u2019s disease: a review of success rates, remission predictors, management of failed surgery, and Nelson\u2019s Syndrome","volume":"23","author":"Kelly","year":"2007","journal-title":"Neurosurg Focus."},{"key":"10.4158\/EP13127.RA_bb0035","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.2005.02380.x","article-title":"Long-term remission rates after pituitary surgery for Cushing\u2019s disease: the need for long-term surveillance","volume":"63","author":"Atkinson","year":"2005","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.4158\/EP13127.RA_bb0040","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","article-title":"Cushing\u2019s syndrome","volume":"367","author":"Newell-Price","year":"2006","journal-title":"Lancet."},{"key":"10.4158\/EP13127.RA_bb0045","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11102-012-0397-5","article-title":"Medical management of Cushing\u2019s disease: what is the future?","volume":"15","author":"Fleseriu","year":"2012","journal-title":"Pituitary."},{"key":"10.4158\/EP13127.RA_bb0050","unstructured":"Korlym\u2122 (mifepristone) full prescribing information. Corcept Therapeutics Inc 2012."},{"key":"10.4158\/EP13127.RA_bb0055","unstructured":"Novartis Pharmaceuticals. Signifor Prescribing Information. 2012. Available at: http:\/\/www.pharma.us.novartis.com\/cs\/www.pharma.us.novartis.com\/product\/ pi\/pdf\/signifor.pdf. Accessed September 5, 2013."},{"key":"10.4158\/EP13127.RA_bb0060","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/00003081-199606000-00024","article-title":"Mifepristone: treatment of Cushing\u2019s syndrome","volume":"39","author":"Sartor","year":"1996","journal-title":"Clin Obstet Gynecol."},{"key":"10.4158\/EP13127.RA_bb0065","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1530\/EJE-07-0458","article-title":"Mifepristone (RU 486) in Cushing\u2019s syndrome","volume":"157","author":"Johanssen","year":"2007","journal-title":"Eur J Endocrinol."},{"key":"10.4158\/EP13127.RA_bb0070","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev.med.48.1.129","article-title":"RU486 (mifepristone): mechanisms of action and clinical uses","volume":"48","author":"Cadepond","year":"1997","journal-title":"Annu Rev Med."},{"key":"10.4158\/EP13127.RA_bb0075","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nrd1255","article-title":"Opportunities in somatostatin research: biological, chemical and therapeutic aspects","volume":"2","author":"Weckbecker","year":"2003","journal-title":"Nat Rev Drug Discov."},{"key":"10.4158\/EP13127.RA_bb0080","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000059430","article-title":"Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells","volume":"75","author":"Strowski","year":"2002","journal-title":"Neuroendocrinology."},{"key":"10.4158\/EP13127.RA_bb0085","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1507\/endocrj.K08E-186","article-title":"Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas","volume":"56","author":"Tateno","year":"2009","journal-title":"Endocr J."},{"key":"10.4158\/EP13127.RA_bb0090","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1210\/jc.2008-2101","article-title":"Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas","volume":"94","author":"de Bruin","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP13127.RA_bb0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.mce.2007.10.015","article-title":"Somatostatin and somatostatin receptors in Cushing\u2019s disease","volume":"286","author":"Hofland","year":"2008","journal-title":"Mol Cell Endocrinol."},{"key":"10.4158\/EP13127.RA_bb0100","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol."},{"issue":"11 Suppl International","key":"10.4158\/EP13127.RA_bb0105","first-page":"28","article-title":"Short-and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats","volume":"28","author":"Schmid","year":"2005","journal-title":"J Endocrinol Invest."},{"key":"10.4158\/EP13127.RA_bb0110","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.01876","article-title":"The multiligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5","volume":"152","author":"Hofland","year":"2005","journal-title":"Eur J Endocrinol."},{"key":"10.4158\/EP13127.RA_bb0115","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP13127.RA_bb0120","unstructured":"ClinicalTrials.gov. NCT00936741. 2013. Available at: http:\/\/clinicaltrials.gov\/show\/NCT00936741. Accessed September 5, 2013."},{"key":"10.4158\/EP13127.RA_bb0125","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing\u2019s disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med."},{"key":"10.4158\/EP13127.RA_bb0130","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0006-2952(99)00010-6","article-title":"Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5","volume":"57","author":"Zambre","year":"1999","journal-title":"Biochem Pharmacol."},{"key":"10.4158\/EP13127.RA_bb0135","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1210\/jc.2006-1578","article-title":"Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets","volume":"92","author":"Singh","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP13127.RA_bb0140","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front Neuroendocrinol."},{"key":"10.4158\/EP13127.RA_bb0145","first-page":"P260","article-title":"Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers","volume":"26","author":"Henry","year":"2011","journal-title":"Endocrine Abstracts."},{"key":"10.4158\/EP13127.RA_bb0150","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.diabet.2012.10.005","article-title":"Management of hyperglycaemia in Cushing\u2019s disease: experts\u2019 proposals on the use of pasireotide","volume":"39","author":"Reznik","year":"2013","journal-title":"Diabetes Metab."},{"key":"10.4158\/EP13127.RA_bb0155","unstructured":"Pivonello R, van Gaal L, Salgado LR, et al. Long-term use of pasireotide results in sustained reductions in UFC and continued improvements in signs and symptoms in patients with Cushing\u2019s disease. In: Program of the 15th Congress of the European Neuroendocrine Association, September 12-15, 2012; Vienna, Austria. Abstract OC05."},{"author":"ClinicalTrials.gov. NCT01582061","key":"10.4158\/EP13127.RA_bb0160"},{"key":"10.4158\/EP13127.RA_bb0165","unstructured":"European Medicines Authority. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. 2013. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_ release\/2013\/07\/WC500146613.pdf. Accessed September 5, 2013."},{"key":"10.4158\/EP13127.RA_bb0170","unstructured":"FDA Drug Safety Communications. FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. 2013. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM362444.pdf. Accessed September 5, 2013."},{"key":"10.4158\/EP13127.RA_bb0175","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","article-title":"Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease","volume":"362","author":"Feelders","year":"2010","journal-title":"N Engl J Med."},{"key":"10.4158\/EP13127.RA_bb0180","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1365-2265.2012.04424.x","article-title":"Webb SM. A reappraisal of the medical therapy with steroidgenesis inhibitors in Cushing\u2019s syndrome","volume":"77","author":"Valassi","year":"2012","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.4158\/EP13127.RA_bb0185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/EJE-07-0514","article-title":"Ketoconazole revisited: a preoperative or postoperative treatment in Cushing\u2019s disease","volume":"158","author":"Castinetti","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP13127.RA_bb0190","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.1995.13.1.157","article-title":"Ketoconazole in the management of paraneoplastic Cushing\u2019s syndrome secondary to ectopic adrenocorticotropin production","volume":"13","author":"Winquist","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP13127.RA_bb0195","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1530\/EJE-10-0382","article-title":"Cabergoline monotherapy in the long-term treatment of Cushing\u2019s disease","volume":"163","author":"Godbout","year":"2010","journal-title":"Eur J Endocrinol."},{"key":"10.4158\/EP13127.RA_bb0200","doi-asserted-by":"crossref","first-page":"968","DOI":"10.4158\/EP10031.OR","article-title":"Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy","volume":"16","author":"Lila","year":"2010","journal-title":"Endocr Pract."},{"key":"10.4158\/EP13127.RA_bb0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","article-title":"Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing\u2019s disease","volume":"13","author":"Vilar","year":"2010","journal-title":"Pituitary."},{"key":"10.4158\/EP13127.RA_bb0210","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","article-title":"The medical treatment of Cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery","volume":"94","author":"Pivonello","year":"2009","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20435578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20435578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/RM75081341544873.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:58:23Z","timestamp":1761515903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20435578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1530891X20435578"],"URL":"https:\/\/doi.org\/10.4158\/ep13127.ra","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pasireotide and Mifepristone: New Options in the Medical Management of Cushing's Disease","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP13127.RA","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}